A study on the efficacy and biogenic adaptability affected by ipragliflozin
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 25 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 02 Jul 2015 New trial record